Previous 10 | Next 10 |
Apollo Endosurgery (APEN) rallies 35% premarket after receiving FDA Breakthrough Device Designation for the Orbera Intragastric Balloon, for use in treating patients with BMI between 30-40 kg/m2 with noncirrhotic nonalcoholic steatohepatitis ((NASH)) with liver fibrosis.he desi...
ASLAN Pharmaceuticals Limited (ASLN) +71% as ASLAN004 shows positive effect in atopic dermatitis.Apollo Endosurgery (APEN) +47% after receiving a Breakthrough Device Designation from the USFDA for the Orbera® Intragastric Balloon.electroCore (ECOR) +39% on exclusive distri...
AUSTIN, TX / ACCESSWIRE / March 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that it has received a Breakthrough Device Designation from the U.S. Food and Drug...
Apollo Endosurgery, Inc. (APEN) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Matt Kreps - IR Todd Newton - CEO Stefanie Cavanaugh - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Presentation Operator Good afternoon, ladies and ...
Apollo Endosurgery (APEN): Q4 GAAP EPS of -$0.14 beats by $0.12.Revenue of $12.86M (+7.3% Y/Y) beats by $1.85M.Press Release For further details see: Apollo Endosurgery EPS beats by $0.12, beats on revenue
Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET AUSTIN, TX / ACCESSWIRE / February 25, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financ...
AUSTIN, TX / ACCESSWIRE / February 22, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial resul...
Apollo Endosurgery ([[APEN]] +12.3%) announced a planned CEO change; effective Mar.1, Charles (Chas) McKhann will become CEO and a board member.Current CEO Todd Newton will assist in an effective transition to Mr. McKhann and has agreed to serve as a consultant t...
Will Transition to Accomplished Commercial and Operational Medtech Veteran Charles Mckhann AUSTIN, TX / ACCESSWIRE / February 8 , 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and b...
AUSTIN, TX / ACCESSWIRE / January 5, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that it will participate in the H.C. Wainwright Bioconnect 2021 Conference taking pl...
News, Short Squeeze, Breakout and More Instantly...
Apollo Endosurgery Inc. Company Name:
APEN Stock Symbol:
NASDAQ Market:
Apollo Endosurgery Inc. Website:
NEW YORK, NY / ACCESSWIRE / February 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Apollo Endosurgery, Inc. (NASDAQ:APEN...
NEW YORK, NY / ACCESSWIRE / January 8, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: KnowBe4, Inc. (NASDAQ:KNBE)'s sale t...
MERIT Trial Selected as 2022 Top Story in Gastroenterology and ASMBS adds Apollo Systems to List of Approved Bariatric Devices AUSTIN, TX / ACCESSWIRE / December 13, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointe...